vs
BGSF, INC.（BGSF）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是BGSF, INC.的1.4倍（$30.3M vs $22.0M），BGSF, INC.净利率更高（-5.3% vs -221.3%，领先216.1%），REGENXBIO Inc.同比增速更快（43.0% vs -9.4%），BGSF, INC.自由现金流更多（$1.7M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -5.3%）
BGSF Inc.是一家总部位于美国的领先人力资源解决方案提供商，提供定制化人员派遣、人才招聘和全流程劳动力管理服务，覆盖信息技术、医疗健康、专业行政、轻工业、创意产业等核心领域，服务北美各规模的企业客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BGSF vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$22.0M
营收增速更快
RGNX
高出52.4%
-9.4%
净利率更高
BGSF
高出216.1%
-221.3%
自由现金流更多
BGSF
多$54.5M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.0M | $30.3M |
| 净利润 | $-1.2M | $-67.1M |
| 毛利率 | 35.0% | — |
| 营业利润率 | -17.6% | -190.0% |
| 净利率 | -5.3% | -221.3% |
| 营收同比 | -9.4% | 43.0% |
| 净利润同比 | -18.2% | -31.2% |
| 每股收益（稀释后） | $-0.12 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGSFRGNX
| Q4 25 | $22.0M | $30.3M | ||
| Q3 25 | $26.9M | $29.7M | ||
| Q2 25 | $23.5M | $21.4M | ||
| Q1 25 | $20.9M | $89.0M | ||
| Q4 24 | $24.3M | $21.2M | ||
| Q3 24 | $29.8M | $24.2M | ||
| Q2 24 | $25.7M | $22.3M | ||
| Q1 24 | $24.5M | $15.6M |
净利润BGSFRGNX
| Q4 25 | $-1.2M | $-67.1M | ||
| Q3 25 | $-5.8M | $-61.9M | ||
| Q2 25 | $-3.7M | $-70.9M | ||
| Q1 25 | $-722.0K | $6.1M | ||
| Q4 24 | $-981.0K | $-51.2M | ||
| Q3 24 | $-804.0K | $-59.6M | ||
| Q2 24 | $-761.0K | $-53.0M | ||
| Q1 24 | $-792.0K | $-63.3M |
毛利率BGSFRGNX
| Q4 25 | 35.0% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.2% | — | ||
| Q4 24 | 35.9% | 70.2% | ||
| Q3 24 | 35.9% | 48.8% | ||
| Q2 24 | 37.3% | 52.5% | ||
| Q1 24 | 38.1% | 72.6% |
营业利润率BGSFRGNX
| Q4 25 | -17.6% | -190.0% | ||
| Q3 25 | -3.5% | -176.3% | ||
| Q2 25 | -18.8% | -296.3% | ||
| Q1 25 | 1.6% | 13.6% | ||
| Q4 24 | -15.7% | -242.1% | ||
| Q3 24 | -3.4% | -256.6% | ||
| Q2 24 | -5.7% | -251.3% | ||
| Q1 24 | 1.7% | -408.8% |
净利率BGSFRGNX
| Q4 25 | -5.3% | -221.3% | ||
| Q3 25 | -21.6% | -208.3% | ||
| Q2 25 | -15.9% | -331.8% | ||
| Q1 25 | -3.5% | 6.8% | ||
| Q4 24 | -4.0% | -241.3% | ||
| Q3 24 | -2.7% | -246.3% | ||
| Q2 24 | -3.0% | -237.7% | ||
| Q1 24 | -3.2% | -405.4% |
每股收益（稀释后）BGSFRGNX
| Q4 25 | $-0.12 | $-1.30 | ||
| Q3 25 | $-0.52 | $-1.20 | ||
| Q2 25 | $-0.34 | $-1.38 | ||
| Q1 25 | $-0.06 | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $-0.07 | $-1.17 | ||
| Q2 24 | $-0.07 | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.1M | $102.7M |
| 总资产 | $57.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BGSFRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | $41.2M | $274.2M | ||
| Q2 25 | $2.8M | $323.3M | ||
| Q1 25 | $2.0M | $267.9M | ||
| Q4 24 | $32.0K | $234.7M | ||
| Q3 24 | $262 | $255.5M | ||
| Q2 24 | $226 | $290.4M | ||
| Q1 24 | $50 | $338.7M |
股东权益BGSFRGNX
| Q4 25 | $48.1M | $102.7M | ||
| Q3 25 | $50.7M | $161.5M | ||
| Q2 25 | $78.3M | $213.7M | ||
| Q1 25 | $81.8M | $274.2M | ||
| Q4 24 | $82.3M | $259.7M | ||
| Q3 24 | $82.9M | $301.4M | ||
| Q2 24 | $83.2M | $348.3M | ||
| Q1 24 | $83.6M | $390.7M |
总资产BGSFRGNX
| Q4 25 | $57.8M | $453.0M | ||
| Q3 25 | $83.6M | $525.2M | ||
| Q2 25 | $149.7M | $581.0M | ||
| Q1 25 | $152.3M | $490.9M | ||
| Q4 24 | $150.1M | $466.0M | ||
| Q3 24 | $157.3K | $519.1M | ||
| Q2 24 | $159.8K | $569.4M | ||
| Q1 24 | $170.6K | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $1.7M | $-52.8M |
| 自由现金流率自由现金流/营收 | 7.6% | -174.0% |
| 资本支出强度资本支出/营收 | 0.1% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-16.0K | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BGSFRGNX
| Q4 25 | $1.7M | $-52.3M | ||
| Q3 25 | $-4.8M | $-56.0M | ||
| Q2 25 | $2.2M | $-49.3M | ||
| Q1 25 | $1.1M | $33.6M | ||
| Q4 24 | $3.2M | $-31.6M | ||
| Q3 24 | $6.5M | $-40.5M | ||
| Q2 24 | $7.3M | $-45.5M | ||
| Q1 24 | $7.4M | $-55.5M |
自由现金流BGSFRGNX
| Q4 25 | $1.7M | $-52.8M | ||
| Q3 25 | $-4.9M | $-56.5M | ||
| Q2 25 | $2.1M | $-49.7M | ||
| Q1 25 | $1.0M | $32.6M | ||
| Q4 24 | $2.5M | $-32.7M | ||
| Q3 24 | $6.5M | $-40.9M | ||
| Q2 24 | $7.3M | $-46.0M | ||
| Q1 24 | $6.9M | $-56.0M |
自由现金流率BGSFRGNX
| Q4 25 | 7.6% | -174.0% | ||
| Q3 25 | -18.1% | -189.9% | ||
| Q2 25 | 9.1% | -232.8% | ||
| Q1 25 | 5.0% | 36.6% | ||
| Q4 24 | 10.2% | -154.2% | ||
| Q3 24 | 21.7% | -168.9% | ||
| Q2 24 | 28.5% | -206.2% | ||
| Q1 24 | 28.1% | -358.5% |
资本支出强度BGSFRGNX
| Q4 25 | 0.1% | 1.7% | ||
| Q3 25 | 0.4% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 3.0% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 2.0% | 3.6% |
现金转化率BGSFRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
